Triple KRAS Pathway Blockade Drives Complete Regression of Pancreatic Tumors in Preclinical Tests
TL;DR Summary
Spanish researchers report a three-drug combo (RMC-6236/daraxonrasib, Afatinib, SD36) that simultaneously targets RAF1 (KRAS downstream), EGFR (upstream) and STAT3 signaling, producing complete regression of pancreatic tumors in orthotopic mouse models and patient-derived tissues with no resistance for more than 200 days, suggesting potential clinical trials for pancreatic ductal adenocarcinoma.
- Drug trio found to block tumour resistance in pancreatic cancer Drug Target Review
- Spanish scientist finds cure for pancreatic cancer in major medical breakthrough Times of India
- Scientists achieve pancreatic tumour regression in breakthrough study Euronews.com
- Scientists Cure Pancreatic Cancer In Mice Without Major Side Effects NDTV
- Pascal Burri: Why this PNAS Study on KRAS-mutant PDAC is More than "Strong Preclinical Data" Oncodaily
Reading Insights
Total Reads
1
Unique Readers
13
Time Saved
11 min
vs 12 min read
Condensed
98%
2,226 → 49 words
Want the full story? Read the original article
Read on Drug Target Review